Is an NCD the Right Move for Your Technology? Lessons from CMS’s Final Decision on Renal Denervation
Published on: 29/10/2025
Learn when to pursue a National Coverage Determination (NCD) and what CMS’s renal denervation decision means for MedTech reimbursement and evidence strategy.
NCDCMSRenal DenervationMedicare Final Decision
Do QALYs Matter in the U.S.?
Published on: 11/03/2025
QALYs are essential in Europe—but not in the U.S. Here's what really drives MedTech coverage decisions and how to pivot.
QALYs and U.S. reimbursementMedicare coverage criteriaPrivate payer strategyCost-effectiveness in healthcareClinical necessitypayer incentivesshort-term cost savingscoverage decisionsCMSpeer-reviewed evidenceHTA comparisonsprovider economicshospital adoption strategyhow U.S. payers make reimbursement decisionswhy cost-effectiveness models don’t work in the U.S.
Payer Policy Is Poised to Unlock the Full Potential of AI in MedTech in 2025
Published on: 17/12/2024
U.S. payers are evolving fast. Here’s how AI-driven MedTech innovators can lead—not wait—for reimbursement models.
value-based reimbursementcoding gapCategory |||permanent codeoutcome-based agreementspayer-aligned metricsmetricsAI MedTechReimbursementCMSHealthcare efficiencyAlternative payment
Medicare Proposes to Approve 80% of Transitional Pass Through Applications for Novel Tech in 2025
Published on: 25/08/2024
CMS is signaling support for innovation. Here's what this policy shift could mean for your device.
TPTTPT PolicyCMSDevice Innovation SupportPayment PathwaysBreakthrough Coverage Incentives
